27 August 2024
Belluscura plc
("Belluscura" or the "Company")
Result of General Meeting
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at the Annual General Meeting held earlier today, all resolutions proposed were duly approved by shareholders:
|
| Total votes for | % of shares voted | Total votes against | % of shares voted | Total votes | Votes withheld |
| Ordinary resolutions |
|
|
|
|
|
|
| Resolution 1: To receive and adopt the report of the directors and the audited accounts of the Company for the period ended 31 December 2023 | 91,444,802 | 99.94 | 55,722 | 0.06 | 91,500,524 | - |
| Resolution 2: To re-elect Simon Neicheril as a director of the Company | 91,426,718 | 99.94 | 54,753 | 0.06 | 91,481,471 | 19,053 |
| Resolution 3: To re-elect Robert Fary as a director of the Company | 91,426,718 | 99.94 | 54,753 | 0.06 | 91,481,471 | 19,053 |
| Resolution 4: To re-elect Paul Tuson as a director of the Company | 91,426,574 | 99.94 | 54,897 | 0.06 | 91,481,471 | 19,053 |
| Resolution 5: To re-appoint Gerald Edelman LLP as auditor to the Company | 91,456,503 | 99.95 | 43,877 | 0.05 | 91,500,380 | 144 |
| Resolution 6: To authorise the directors to determine the remuneration of the auditors | 91,442,594 | 99.96 | 38,877 | 0.04 | 91,481,471 | 19,053 |
| Resolution 7: To grant the directors authority to allot shares pursuant to Section 551 of the Companies Act 2006 and grant rights to subscribe for, or convert any security into, shares | 91,439,344 | 99.93 | 61,180 | 0.07 | 91,500,524 | - |
| Special resolutions | | | | | | |
| Resolution 8: To dis-apply pre-emption rights pursuant to Section 570 of the Companies Act 2006 | 86,818,255 | 94.90 | 4,663,216 | 5.10 | 91,481,471 | 19,053 |
| Resolution 9: To authorise the directors to make market purchases | 86,896,258 | 94.97 | 4,604,266 | 5.03 | 91,500,524 | - |
For further information please contact:
|
Belluscura plc | Tel: +44 (0)20 3128 8100 |
| Adam Reynolds, Chairman Robert Rauker, Chief Executive Officer Simon Neicheril, Chief Financial Officer | |
| | |
| SPARK Advisory Partners Limited (Nominated Adviser) | Tel: +44 (0)20 3368 3550 |
| Neil Baldwin / Jade Bayat | |
| | |
| Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
| James Serjeant / Russell Cook | |
| | |
| MHP Group (Financial PR & Investor Relations) | Tel: +44 (0)20 3128 8100 |
| Katie Hunt / Matthew Taylor | belluscura@mhpgroup.com |
About Belluscura plc (https://belluscura.com/)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.